Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Brain region specific actions of regulator of G protein signaling 4 oppose morphine reward and dependence but promote analgesia.

Han MH, Renthal W, Ring RH, Rahman Z, Psifogeorgou K, Howland D, Birnbaum S, Young K, Neve R, Nestler EJ, Zachariou V.

Biol Psychiatry. 2010 Apr 15;67(8):761-9. doi: 10.1016/j.biopsych.2009.08.041. Epub 2009 Nov 14.

2.

Nucleus accumbens-specific interventions in RGS9-2 activity modulate responses to morphine.

Gaspari S, Papachatzaki MM, Koo JW, Carr FB, Tsimpanouli ME, Stergiou E, Bagot RC, Ferguson D, Mouzon E, Chakravarty S, Deisseroth K, Lobo MK, Zachariou V.

Neuropsychopharmacology. 2014 Jul;39(8):1968-77. doi: 10.1038/npp.2014.45. Epub 2014 Feb 24.

3.

A unique role of RGS9-2 in the striatum as a positive or negative regulator of opiate analgesia.

Psifogeorgou K, Terzi D, Papachatzaki MM, Varidaki A, Ferguson D, Gold SJ, Zachariou V.

J Neurosci. 2011 Apr 13;31(15):5617-24. doi: 10.1523/JNEUROSCI.4146-10.2011. Erratum in: J Neurosci. 2011 May 18;31(20):7578. Psigfogeorgou, Kassi [corrected to Psifogeorgou, Kassi].

4.

Regulator of G protein signaling 4 [corrected] is a crucial modulator of antidepressant drug action in depression and neuropathic pain models.

Stratinaki M, Varidaki A, Mitsi V, Ghose S, Magida J, Dias C, Russo SJ, Vialou V, Caldarone BJ, Tamminga CA, Nestler EJ, Zachariou V.

Proc Natl Acad Sci U S A. 2013 May 14;110(20):8254-9. doi: 10.1073/pnas.1214696110. Epub 2013 Apr 29. Erratum in: Proc Natl Acad Sci U S A. 2013 Jul 9;110(28):11660.

5.

Splicing factor transformer-2β (Tra2β) regulates the expression of regulator of G protein signaling 4 (RGS4) gene and is induced by morphine.

Li SJ, Li Y, Cui SC, Qi Y, Zhao JJ, Liu XY, Xu P, Chen XH.

PLoS One. 2013 Aug 19;8(8):e72220. doi: 10.1371/journal.pone.0072220. eCollection 2013.

6.

RGSZ1 and GAIP regulate mu- but not delta-opioid receptors in mouse CNS: role in tachyphylaxis and acute tolerance.

Garzón J, Rodríguez-Muñoz M, López-Fando A, García-España A, Sánchez-Blázquez P.

Neuropsychopharmacology. 2004 Jun;29(6):1091-104.

7.

Essential role for RGS9 in opiate action.

Zachariou V, Georgescu D, Sanchez N, Rahman Z, DiLeone R, Berton O, Neve RL, Sim-Selley LJ, Selley DE, Gold SJ, Nestler EJ.

Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13656-61. Epub 2003 Oct 31.

8.

Intrathecal RGS4 inhibitor, CCG50014, reduces nociceptive responses and enhances opioid-mediated analgesic effects in the mouse formalin test.

Yoon SY, Woo J, Park JO, Choi EJ, Shin HS, Roh DH, Kim KS.

Anesth Analg. 2015 Mar;120(3):671-7. doi: 10.1213/ANE.0000000000000607.

PMID:
25695583
9.

The RGSZ2 protein exists in a complex with mu-opioid receptors and regulates the desensitizing capacity of Gz proteins.

Garzón J, Rodríguez-Muñoz M, López-Fando A, Sánchez-Blázquez P.

Neuropsychopharmacology. 2005 Sep;30(9):1632-48.

10.

Loss of morphine reward and dependence in mice lacking G protein-coupled receptor kinase 5.

Glück L, Loktev A, Moulédous L, Mollereau C, Law PY, Schulz S.

Biol Psychiatry. 2014 Nov 15;76(10):767-74. doi: 10.1016/j.biopsych.2014.01.021. Epub 2014 Feb 3.

11.

Differential modulation of mu- and delta-opioid receptor agonists by endogenous RGS4 protein in SH-SY5Y cells.

Wang Q, Liu-Chen LY, Traynor JR.

J Biol Chem. 2009 Jul 3;284(27):18357-67. doi: 10.1074/jbc.M109.015453. Epub 2009 May 5.

12.

R7BP modulates opiate analgesia and tolerance but not withdrawal.

Terzi D, Cao Y, Agrimaki I, Martemyanov KA, Zachariou V.

Neuropsychopharmacology. 2012 Mar;37(4):1005-12. doi: 10.1038/npp.2011.284. Epub 2011 Nov 16.

13.

Galanin protects against behavioral and neurochemical correlates of opiate reward.

Hawes JJ, Brunzell DH, Narasimhaiah R, Langel U, Wynick D, Picciotto MR.

Neuropsychopharmacology. 2008 Jul;33(8):1864-73. Epub 2007 Oct 24.

14.

Differential control of opioid antinociception to thermal stimuli in a knock-in mouse expressing regulator of G-protein signaling-insensitive Gαo protein.

Lamberts JT, Smith CE, Li MH, Ingram SL, Neubig RR, Traynor JR.

J Neurosci. 2013 Mar 6;33(10):4369-77. doi: 10.1523/JNEUROSCI.5470-12.2013.

15.

Regulation of RGS proteins by chronic morphine in rat locus coeruleus.

Gold SJ, Han MH, Herman AE, Ni YG, Pudiak CM, Aghajanian GK, Liu RJ, Potts BW, Mumby SM, Nestler EJ.

Eur J Neurosci. 2003 Mar;17(5):971-80.

PMID:
12653973
16.

RGS9 proteins facilitate acute tolerance to mu-opioid effects.

Garzón J, Rodríguez-Díaz M, López-Fando A, Sánchez-Blázquez P.

Eur J Neurosci. 2001 Feb;13(4):801-11.

PMID:
11207815
17.

RGS9-2 is a negative modulator of mu-opioid receptor function.

Psifogeorgou K, Papakosta P, Russo SJ, Neve RL, Kardassis D, Gold SJ, Zachariou V.

J Neurochem. 2007 Oct;103(2):617-25. Epub 2007 Aug 23.

18.

Mu opiate receptor gene dose effects on different morphine actions: evidence for differential in vivo mu receptor reserve.

Sora I, Elmer G, Funada M, Pieper J, Li XF, Hall FS, Uhl GR.

Neuropsychopharmacology. 2001 Jul;25(1):41-54.

19.

A role of RGS proteins in drug addiction.

Hooks SB, Martemyanov K, Zachariou V.

Biochem Pharmacol. 2008 Jan 1;75(1):76-84. Epub 2007 Aug 11. Review.

PMID:
17880927
20.

The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics.

Raehal KM, Bohn LM.

Neuropharmacology. 2011 Jan;60(1):58-65. doi: 10.1016/j.neuropharm.2010.08.003. Epub 2010 Aug 14.

Items per page

Supplemental Content

Write to the Help Desk